Journal of Oncology Pharmacy Practice最新文献

{"title":"Contamination on the external surface of hazardous drug vials wrapped in Vial Protect Pack shrink tack labels.","authors":"Paul Sessink, Motohiko Sano","doi":"10.1177/10781552261433917","DOIUrl":"10.1177/10781552261433917","url":null,"abstract":"<p><p>PurposeExternal contamination of hazardous drug vials poses significant risks of environmental contamination and occupational exposure. This study evaluated the effectiveness of Vial Protect Pack shrink-tack labels (VPP I and II) in preventing surface contamination on vials containing doxorubicin, paclitaxel, and gemcitabine.MethodsA total of 150 vials from 14 production lots were tested: 60 doxorubicin vials (10 mg, 6 lots) with VPP I, 60 paclitaxel vials (30 mg/5 mL, 5 lots) with VPP II, and 30 gemcitabine vials (200 mg/5 mL, 3 lots) with VPP II. External vial surfaces were sampled using standardized wipe protocols and analyzed by liquid chromatography tandem mass spectrometry.ResultsAll 150 vials showed contamination levels below the analytical detection limits, indicating no measurable drug residues on external vial surfaces across all drugs and production lots tested. No lot-to-lot variation was observed.ConclusionVPP shrink-tack labels maintained external contamination below analytical detection limits on all tested vials, demonstrating their effectiveness as an engineering control to reduce occupational exposure. Incorporating vials with validated contamination-control technology into hospital procurement policies may enhance healthcare worker protection and support safer compounding practices.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261433917"},"PeriodicalIF":0.9,"publicationDate":"2026-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147494202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacist-led anticoagulation care in cancer: Associations with bleeding and VTE recurrence.","authors":"Sajjad Ullah, Inayat Ur Rehman, Javeria Khalid, Yasar Shah, Omar Akhlaq Bhutta, Long Chiau Ming","doi":"10.1177/10781552261422413","DOIUrl":"https://doi.org/10.1177/10781552261422413","url":null,"abstract":"<p><p>ObjectivesVenous thromboembolism (VTE) is a major complication in cancer patients, resulting in heightened mortality and morbidity. Managing recurrence of VTE or risk of bleeding is a major challenge among cancer patients receiving anticoagulants. Therefore, this study assesses the effects of pharmacist-led interventions on the occurrence of either bleeding or recurrent VTE among cancer patients.MethodsThis retrospective cross-sectional study analyzed data from a tertiary care cancer hospital in Pakistan, collected from 2019 to 2023. The study included cancer patients aged ≥18 years diagnosed with VTE. The primary exposure variable was pharmacist-led interventions, and the primary outcome was a composite endpoint defined as occurrence of wither bleeding or recurrent VTE. Patient's demographics, cancer type, comorbidities, and type of anticoagulants were controlled as covariates. The chi-square test and t-test were used in bivariate analyses, at a significance level of p < 0.05. A multivariate logistic regression model was used to determine the association between pharmacist-led interventions and the risk of bleeding or recurrent VTE.ResultsOf the 210 individuals, 34.3% (n = 72) experienced the composite outcome of bleeding or recurrent VTE. Patients on subcutaneous anticoagulants had a markedly greater incidence of events in contrast to those on oral anticoagulants (77.8% vs. 22.2% respectively, p = 0.017). Metastatic cancer (80.6% vs. 52.1%, p = 0.0001) and surgical procedures (70.8% vs.47.2%, p = 0.0014) were significant predictors of the composite outcome. Interventions guided by pharmacists markedly decreased the likelihood of the composite outcome (aOR = 0.44, 95% CI: 0.20-0.97) by the optimization of dose, monitoring, and patient education.ConclusionPharmacist-led interventions markedly enhance outcomes among cancer patients receiving anticoagulant treatment by decreasing the risk of outcome of bleeding or recurrent VTE. The findings highlight the necessity of including pharmacists into multidisciplinary cancer care teams. Subsequent research should investigate these therapies in more diverse groups to enhance the validation of their effects.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261422413"},"PeriodicalIF":0.9,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147474110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the incidence of thrombosis in patients with concurrent second-generation androgen receptor inhibitor therapy and direct oral anticoagulants: A retrospective chart review.","authors":"Zachary Larson, Cassia Griswold","doi":"10.1177/10781552261430330","DOIUrl":"https://doi.org/10.1177/10781552261430330","url":null,"abstract":"<p><strong>Introduction: </strong>Many patients with prostate cancer have an indication for anticoagulation. This presents a pharmacokinetic dilemma as enzalutamide and apalutamide have significant effects on the metabolism of direct oral anticoagulants. To date, data on coadministration of these agents is limited to pharmacokinetic studies and post-hoc analysis, which suggest no deleterious effects. Our study seeks to elucidate whether the concomitant administration of enzalutamide or apalutamide with apixaban or rivaroxaban results in a clinically meaningful change in thromboembolic events.</p><p><strong>Methods: </strong>We conducted a retrospective, observational cohort study of adult prostate cancer patients on concomitant apalutamide or enzalutamide and apixaban or rivaroxaban for ≥ 3 months from January 1, 2018 to August 9, 2024 at all 3 tertiary sites of our care network. The primary outcome was incidence of deep vein thrombosis, pulmonary embolism, or ischemic stroke. The secondary outcomes included the incidence of switching of anticoagulant therapy or prostate-directed therapy due to concern for drug-drug interaction. The secondary outcomes were assessed in the entire cohort without exclusion.</p><p><strong>Results: </strong>A total of 500 patients were assessed for eligibility, of which 94 were included in the final analysis of primary outcome. The primary outcome occurred in 4 patients (4.3%). The switching of anticoagulant therapy occurred in 32 patients (6.4%). The switching of prostate-directed therapy occurred in 5 patients (1%).</p><p><strong>Conclusion: </strong>This study suggests that there is not an increased incidence of VTE or stroke when compared to historical controls. This study may help clinicians make risk benefit decisions regarding concurrent therapies.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261430330"},"PeriodicalIF":0.9,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147473979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary central nervous system lymphoma: Evolving treatment strategies to achieve improved long-term disease control.","authors":"Moza Hamoud, Victor M Samperio, Ion Codreanu, Constantin A Dasanu","doi":"10.1177/10781552261430675","DOIUrl":"https://doi.org/10.1177/10781552261430675","url":null,"abstract":"<p><p>ObjectiveDespite high initial response rates to chemotherapy, long-term disease control in primary central nervous system lymphoma (PCNSL) remains challenging, with high relapse rates and no universally accepted standard for induction or consolidation therapy. This review discusses current strategies, new advancements and clinical trial results for PCNSL.Data SourcesAn extensive Medline, Embase and Cochrane search of peer-reviewed sources reporting on pharmacotherapy of PCNSL was performed (1/1/2000-12/31/2025). Analysis of original research including clinical trial results, retrospective series and other reports were included in this review.Data SummaryThis review summarizes the current understanding of PCNSL, including epidemiology, clinical presentation, diagnostic evaluation, and response assessment, with a focus on pharmacologic management. We discuss modern induction strategies centered on high-dose methotrexate (HD-MTX) and rituximab, consolidation approaches including reduced-dose whole-brain radiotherapy (WBRT), autologous stem cell transplantation (ASCT), and maintenance strategies, as well as emerging therapies for relapsed or refractory disease. A case of a 76-year-old patient achieving sustained remission exceeding seven years following rituximab plus HD-MTX induction and consolidative therapy is presented to illustrate the potential for durable disease control and even cure. These data underscore the importance of individualized treatment selection based on patient age, fitness level and response to induction and highlight that lasting remission is achievable in select patients with optimized, multimodal therapy.ConclusionsDespite its rarity, PCNSL remains a therapeutically challenging malignancy. HD-MTX-based chemotherapy remains the cornerstone of first-line treatment, and the addition of rituximab has been associated with more sustained responses. Although relapses are not uncommon, long-term remission is achievable. Clinical trials of newer agents, alone or added to a backbone of traditional chemotherapy, are warranted in the 1^st and subsequent lines of therapy. Continued prospective research and international collaboration are essential to integrate precision oncology to the bedside of patients with PCNSL.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261430675"},"PeriodicalIF":0.9,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147499315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint inhibitors for the treatment of cancer in people living with HIV.","authors":"Sara Rodríguez-Tierno, Jorge Fernández-Fradejas, Manuel Vélez-Díaz-Pallarés, Teresa Alonso-Gordoa, María Jesús Vivancos-Gallego, Ana Álvarez-Díaz, Hilario Martínez-Barros","doi":"10.1177/10781552261430873","DOIUrl":"https://doi.org/10.1177/10781552261430873","url":null,"abstract":"<p><p>ObjectivesTo describe the impact of immune checkpoint inhibitors (ICPi) in infection control in people living with HIV (PLWHIV) and to explore their safety compared with a matched cohort of people living without HIV (PLWOHIV). Secondary, to report inclusion and exclusion criteria for PLWHIV in clinical trials (CT) with ICPi.MethodsObservational, retrospective, single-center study. PLWHIV initiating ICPi from January 2018 until June 2023 were included. Biomarkers of HIV infection control were collected at baseline and after ICPi initiation. Safety data were compared with a 1:2 matched cohort of PLWOHIV. CT with ICPi starting recruitment between January 2018 and December 2022 were analyzed.ResultsTwenty-eight PLWHIV were included, most male (22; 78.6%), median age 57 years (IQI 55.0-60.0). Follow-up data on infection control were available in 19 (67.9%) patients. In 17 (89.5%) the viral load was <200 copies/ml throughout the complete follow-up, in 13 (68.4%) CD4 + remained above 200 cells/µl and in 13 (68.4%) the CD4/CD8 ratio persisted ≥0.4. In 11 (57.9%) all three conditions were met. Forty-eight PLWOHIV were identified for the matched cohort. Adverse events rates were similar between groups.A total of 126 CT with ICPi were identified: 91 (72.2%) explicitly excluded PLWHIV, 24 (19.0%) did not mention HIV infection, and 11 (8.7%) allowed their inclusion under certain conditions.ConclusionsICPi in PLWHIV appeared to have a safety profile similar to that observed in PLWOHIV without evident negative effects on viral control. However, PLWHIV remain frequently excluded from ICPi CT.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261430873"},"PeriodicalIF":0.9,"publicationDate":"2026-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147458283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric pharmaceutical forms in oncology: A review of galenic challenges, difficulties encountered in hospital practice, and perspectives offered by new technologies.","authors":"Seham El Deeb, Ismail Bennani, Ali Cherif Chefchaouni, Imane Toughrai, Kamelia Amazian, Abdeslam El Kartouti","doi":"10.1177/10781552261430349","DOIUrl":"10.1177/10781552261430349","url":null,"abstract":"<p><p>ObjectiveTo review the pharmaceutical challenges associated with pediatric anticancer formulations and discuss current limitations, hospital practice difficulties, and emerging technological strategies to improve safety, accuracy, and acceptability of pediatric oncology treatments.Data SourcesRelevant literature on pediatric oncology formulations, compounding practices, and innovative drug-delivery technologies was analyzed using a narrative review approach.Data SummaryPediatric oncology presents unique pharmaceutical challenges due to the limited availability of age-appropriate anticancer formulations. Because most anticancer drugs are developed for adults, pediatric treatment frequently relies on off-label use and extemporaneous manipulation of dosage forms, raising concerns regarding dose accuracy, stability, excipient-related toxicity, and occupational safety in hospital settings. Extemporaneous compounding may lead to dosing variability, reduced stability, and healthcare professional exposure to hazardous drugs. Emerging approaches, including 3D-printed individualized mini-tablets, orodispersible films, nanocarrier-based delivery systems, physiologically based pharmacokinetic modeling, and therapeutic drug monitoring, show potential to improve dosing precision, safety, and treatment acceptability.ConclusionsThe lack of suitable pediatric anticancer formulations remains a major barrier to safe and effective therapy. Hospital pharmacists play a central role in mitigating formulation-related risks through controlled preparation and innovative practices. Integration of emerging pharmaceutical technologies into clinical practice may enable safer, more standardized, and individualized pediatric oncology treatments.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261430349"},"PeriodicalIF":0.9,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147433593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential impact of clinical pharmacist services on mitigating oral and nutritional complications and quality of life in hospitalized patients with hematological malignancies.","authors":"Aygül Köseoğlu, Anmar Al-Taie, Mesut Sancar, Leylagül Kaynar, Gülden Zehra Omurtag","doi":"10.1177/10781552261425975","DOIUrl":"https://doi.org/10.1177/10781552261425975","url":null,"abstract":"<p><p>BackgroundsThe prevalence of oral and malnutrition disorders is quite high in patients with hematological malignancies which may complicate cancer management resulting in poor prognosis, lower quality of life (QoL) and more deterioration of patient-related outcomes. The aim of this study was to assess the impact of clinical pharmacist provision of patient education and counseling services on mitigating the occurrence and severity of oral and nutritional complications alongside improving the quality of life from chemotherapy in hospitalized hematological patients in Istanbul, Türkiye.MethodsA single-centre prospective, randomized-controlled study conducted in hospitalized cancer patients with new diagnosis of hematological malignancies in the hematology clinic service of Istanbul Medipol University Hospital between September 2022 and March 2023. Patients were assigned into two groups with one-month follow-up as a control group (CG) who received oncology care and an intervention group (IG) who received both oncology care and intensive and appropriate education and counseling services by the clinical pharmacist regarding the incidence of oral and nutritional complicationsResultsCompared to the CG and after the provision of patient education and counselling by the clinical pharmacist, patients within the IG showed statistically significant lower incidence and severity of oral mucositis (P < 0.0001), a significantly decreased total protein and serum albumin (P < 0.0001). 61.4% of patients in the CG were at nutritional risk compared to 53.1% of patients in the IG and a significant improvement in the QoL regarding physical, vital, cognitive, emotional, social functions and general health status.ConclusionsHospitalized cancer patients with hematological malignancies reported improved patient-related outcomes regarding oral and nutritional complications alongside improved quality of life after the provision of patient education and counseling by the clinical pharmacist which can be considered a priority strategy for providing well-structured cancer-related supportive care.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261425975"},"PeriodicalIF":0.9,"publicationDate":"2026-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147348568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world effectiveness of 2-weekly (Q2W) versus 4-weekly (Q4W) nivolumab for treatment of adjuvant and advanced melanoma at BC Cancer.","authors":"Ruishen Yu, Kiran Gill, Shirley St Yeung, Jennifer Truong, Victoria Kletas, Kimberly Schaff, Lynne Nakashima","doi":"10.1177/10781552261425252","DOIUrl":"https://doi.org/10.1177/10781552261425252","url":null,"abstract":"<p><p>IntroductionNivolumab has demonstrated promising survival outcomes in melanoma. Original dosing was 3 mg/kg (maximum 240 mg) intravenously (IV) every two weeks (Q2 W). Based on pharmacokinetic and pharmacodynamic studies demonstrating similar efficacy, 6 mg/kg (maximum 480 mg) IV every four weeks (Q4 W) dosing was introduced. However, real-world effectiveness data remains limited. This study analyzed real-world effectiveness between Q2 W versus Q4 W nivolumab dosing intervals in adjuvant and metastatic melanoma patients.MethodsA retrospective chart review was conducted to compare overall survival (OS), progression free survival (PFS), prescribing trends, and reasons for switching intervals between Q2 W versus Q4 W nivolumab dosing in advanced and adjuvant melanoma patients. Patients started nivolumab between January 1st, 2019, to December 31st, 2020, and were followed up until July 31st, 2024. Patients were stratified based on the treatment intent.ResultsSeventy patients (advanced n = 27, adjuvant n = 43) were included. Baseline characteristics were similar between the dosing groups for each treatment intent. In the advanced group, the median time of PFS was 7.8 months (95% CI 0.0 to 48.9 months) for Q2 W group versus 11.7 months (95% CI 0.0 to 33.7 months) for the Q4 W group. The median time of OS was 32.0 months (95% CI 0.0 to 107.2 months) for the Q2 W group compared to 25.2 months (95% CI 0 to 66.7 months) for the Q4 W group. Meanwhile, in the adjuvant group, OS and PFS outcomes were not reached at follow-up: 14/20 (70.0%) and 13/23 (56.5%) patients have not progressed in the Q2 W and Q4 W groups respectively. There were 16/20 (80.0%) and 17/23 (73.9%) who were still alive at the end of follow up in the Q2 W and Q4 W groups, respectively.ConclusionsIn advanced melanoma patients, Q4 W dosing showed comparable effectiveness with Q2 W dosing. Based on these results and previous real-world evidence demonstrating similar safety profiles, Q4 W dosing provides an alternative dosing interval that may lead to decreased healthcare utilization and exposure, while supporting environmental initiatives.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261425252"},"PeriodicalIF":0.9,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147344187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterizing pharmacist impact in maintenance therapy for adolescent and young adults with acute lymphoblastic leukemia treated with CALGB 10403 protocol.","authors":"Cami Andreini, Brian Lam, Taylor Dennison, Jessica Auten, Kaitlyn M Buhlinger, Stephen M Clark, Benyam Muluneh, Allison B Carroll, Laura Klos, Wenqing Zhu, Hailey Hirata, Bianka Patel","doi":"10.1177/10781552261421898","DOIUrl":"https://doi.org/10.1177/10781552261421898","url":null,"abstract":"<p><p>IntroductionCancer and Leukemia Group B (CALGB) 10403 is a pediatric-inspired treatment protocol for adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) patients. During Course V maintenance, patients receive mercaptopurine (6MP) and oral methotrexate (MTX), which require frequent laboratory monitoring and dose adjustments. The purpose of this study was to characterize the impact of pharmacist intervention on the safe implementation of Course V.MethodsThis single-center, retrospective chart review included AYA patients with B- or T-cell ALL who initiated treatment with CALGB 10403 at UNCMC between April 2014 and April 2024. The primary endpoint was the rate of pharmacist-driven 6MP and MTX holds per protocol during Course V. The key secondary endpoint was the rate of pharmacist-driven 6MP and MTX dose adjustments during Course V.ResultsAll 18 patients required chemotherapy dose adjustments. Pharmacists led 6MP and MTX dose interruptions in 25 of 35 (71.4%) instances and dose modifications in 85 of the 140 (60.7%) instances. With the addition of a second pharmacist in the leukemia clinic, the monthly rate of pharmacist-led dose holds and modifications for 6MP and MTX increased by over four-fold.ConclusionPharmacists played a significant role in the safe administration of 6MP and MTX, particularly with the addition of a second clinic pharmacist. This study demonstrates the value of pharmacist involvement in optimizing patient safety during treatment of ALL.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261421898"},"PeriodicalIF":0.9,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147343664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medication regimen complexity and hospital readmissions in older cancer patients.","authors":"Aslınur Albayrak, Tuğçe Yaka, Nurgül Yaşar","doi":"10.1177/10781552261428430","DOIUrl":"https://doi.org/10.1177/10781552261428430","url":null,"abstract":"<p><p>IntroductionMedication complexity is associated with the number of drugs, dosing frequency, dosage form, and additional instructions. Some studies have shown that high medication complexity is associated with several adverse outcomes, including hospitalization, prolonged hospital stay, readmission, and non-compliance with medication, but studies in older cancer patients are quite limited<b>.</b> The primary aim of this study is to determine the association between the Medication Regimen Complexity Index (MRCI) score and readmission to the hospital for any reason within 30 and 90 days. The secondary purpose was to identify the risk factors associated with the MRCI score.MethodsThis retrospective study included patients with cancer who were hospitalized in the oncology services of the Süleyman Demirel University Research and Practice Hospital between June 2022 and November 2023<b>.</b> Patients with cancer aged > 65 years were included in the study. The MRCI was used to determine drug complexity.ResultsThe median number of medications used by patients was 6 (IQR, 5-8), and the polypharmacy rate was 79.6%. The median MRCI score was 24 (IQR, 17-31). The total number of medications and age were significant predictors of the MRCI score (p < 0.05). In logistic regression models, the MRCI score was associated with readmission to hospital within 30 and 90 days. (p < 0.05).ConclusionIn older adult cancer patients, reducing medication complexity as part of medication management may be beneficial in reducing the risk of hospital readmission.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261428430"},"PeriodicalIF":0.9,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147326280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}